Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial
Background Limited options result in objective responses in patients with well-differentiated neuroendocrine tumors (WD-NET). We tested the efficacy of dual immune checkpoint blockade in patients with WD-NET. Methods We planned a phase II clinical trial in patients with WD-NET who progressed within the past 12 months to standard treatments. Patients received ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks for up to 2 years. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Using Simon’s 2-stage design, the study planned to accrue 56 patients. This regimen would be considered promising if ORR >15%. Results Nine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders. Conclusions The combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure. Clinical trial registration https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521
Authors
- Benjamin Philip Levy (ORCID: https://orcid.org/0009-0005-2331-8542)
- Julie Renee Brahmer (ORCID: https://orcid.org/0000-0002-2443-8395)
- Robert A. Anders (ORCID: https://orcid.org/0000-0002-2363-9072)
- Ana De Jesus‐Acosta (ORCID: https://orcid.org/0000-0002-3225-3024)
- Susan Combs Scott (ORCID: https://orcid.org/0000-0002-1797-1685)
- Elizabeth M. Jaffee (ORCID: https://orcid.org/0000-0003-3841-6549)
- Suqi Ke (ORCID: https://orcid.org/0009-0002-5088-322X)
- Kristen Ashley Marrone (ORCID: https://orcid.org/0000-0001-5319-824X)
- Patrick M. Forde (ORCID: https://orcid.org/0000-0001-6925-6344)
- Christine L. Hann (ORCID: https://orcid.org/0000-0002-1467-5557)
- Qingfeng Zhu
- Chen Hu
- Valsamo Anagnostou
- Peter Bela Illei
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fimmu.2026.1824034
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00